Background of the Invention Chronic obstructive pulmonary disease (COPD) is an umbrella term frequently used to describe two conditions of fixed airways disease, chronic bronchitis and emphysema. Chronic bronchitis and emphysema are most commonly caused by smoking; approximately 90% of patients with COPD are or were smokers. Although approximately 50% of smokers develop chronic bronchitis, only 15% of smokers develop disabling airflow obstruction. Certain animals, particularly horses, suffer from COPD as well.

The airflow obstruction associated with COPD is progressive, may be accompanied by airway hyperreactivity, and may be partially reversible. Non- specific airway hyper-responsiveness may also play a role in the development of COPD and may be predictive of an accelerated rate of decline in lung function in smokers.

COPD is a significant cause of death and disability. It is currently the fourth leading cause of death in the United States and Europe. Treatment guidelines advocate early detection and implementation of smoking cessation programs to help reduce morbidity and mortality due to the disease. However, early detection and diagnosis has been difficult for a number of reasons.

COPD takes years to develop and smokers often deny any ill effects from smoking, attributing the early warning signs of increased breathlessness as a sign of age. Similarly, acute episodes of bronchitis often are not recognized by the general practitioner as early signs of COPD. Many patients exhibit features of more than one disease (e. g. chronic bronchitis or asthmatic bronchitis) making precise diagnosis a challenge, particularly in early disease. Also, many patients do not seek medical help until they are experiencing more severe symptoms associated with reduced lung function, such as dyspnea, persistent cough, and sputum production.

As a consequence, the vast majority of patients are not diagnosed or treated until they are in a more advanced stage of disease.

There is a need for a new approach to treating COPD. This invention provides one such approach.

Summary of the Invention This invention covers a method for the prophylaxis or treatment of COPD in a mammal by administering to a mammal in need thereor an effective amount of a compound of Formula (I) alone or in admixture with a pharmaceutically acceptable excipient wherein Formula (I) comprises:

wherein: Rl is- (CR4R5) nCW O (CR4R5) mR6,- (CR4R5) nC (O) NR4 (CR4R5) mR6,- (CR4R5) nO (CR4R5) mR6, or- (CR4R5) rR6 wherein the alkyl moieties may be optionally substituted with one or more halogens; <BR> <BR> m is 0 to 2;<BR> <BR> <BR> n is 1 to 4; r is 0 to 6; R4 and R5 are independently selected from hydrogen or a C1-2 alkyl ; R6 is hydrogen, methyl, hydroxyl, aryl, halo substituted aryl, aryloxyC 1-3 alkyl, halo substituted aryloxyC1-3 alkyl, indanyl, indenyl, C7 11 polycycloalkyl, tetrahydrofuranyl, furanyl, tetrahydropyranyl, pyranyl, tetrahydrothienyl, thienyl, tetrahydrothiopyranyl, thiopyranyl, C3_6 cycloalkyl, or a C4_6 cycloalkyl containing one or two unsaturated bonds, wherein the cycloalkyl and heterocyclic moieties may be optionally substituted by OH, 1 to 3 methyl groups or one ethyl group; provided that: a) when R6 is hydroxyl, then m is 2; or b) when R6 is hydroxyl, then r is 2 to 6; or c) when R6 is 2-tetrahydropyranyl, 2-tetrahydrothiopyranyl, 2-tetrahydrofuranyl, or 2-tetrahydrothienyl, then m is 1 or 2; or d) when R6 is 2-tetrahydropyranyl, 2-tetrahydrothiopyranyl, 2-tetrahydrofuranyl, or 2-tetrahydrothienyl, then r is 1 to 6; e) when n is 1 and m is 0, then R6 is other than H in - (CR4R5) nO (CR4R5) mR6 ; X is YR2, halogen, nitro, NR4R5, or formyl amine; Y is O or S (O) m'; m'is 0,1, or 2; X2 is O or NR8; X3 is hydrogen or X; X4is

X5 is H, R9, OR8, CN, C (O) Rg, C (O) OR8, C (O) NR8R8, or NR8R8; R2 is independently selected from the group consisting of-CH3 and- CH2CH3 optionally substituted by 1 or more halogens; s is 0 to 4; R3 is hydrogen, halogen, Cl-4 alkyl, CH2NHC (O) C (O) NH2, halo- substituted C1-4 alkyl,-CH=CRgRg, cyclopropyl optionally substituted by Rgs, CN, ORg, CH20Rg, NR8R10, CH2NR8R10 C (Z')H, H,C (0)ORg, C (O) NR8R10, or C#CR8'; Z'Z'is NOR8,NCN,C(-CN)2,CR8CN,CR8NO2,CR8C(O)OR8,NR9, CRgC (O) NRgRg, C (-CN) N02, C (-CN) C (O) OR9, or C (-CN) C (O) NRgRg; Z is C (Y')R14, C(O)OR14, C(Y')NR10R14, C(NR10)NR10R14, CN, C (NOR8) R14, C (O) NRgNRgC (O) Rg, C (O) NRgNRIORl4, C (NOR14) Rg, C (NR8) NR10R14, C (NR14) NR8R8, C (NCN) NR10Rl4, C (NCN) SR9, (2-, 4-or 5-imidazolyl), (3-, 4-or 5-pyrazolyl), (4-or 5-triazolyl [1,2,3]), (3-or 5-triazolyl [1,2,4]), (5-tetrazolyl), (2-, 4-or 5-oxazolyl), (3-, 4-or 5-isoxazolyl), (3- or 5-oxadiazolyl [1,2,4]), (2-oxadiazolyl [1,3,4]), (2-thiadiazolyl [1,3,4]), (2-, 4-, or 5-thiazolyl), (2-, 4-, or 5-oxazolidinyl), (2-, 4-, or 5-thiazolidinyl), or (2-, 4-, or 5-imidazolidinyl); wherein all of the heterocylic ring systems may be optionally substituted one or more times by R14; the dotted line in formula (a) represents a single or double bond; Y'isOorS; R7 is- (CR4R5) qR 12 or C 1-6 alkyl wherein the R 12 or C1-6 alkyl group is optionally substituted one or more times by C 1-2 alkyl optionally substituted by one to three fluorines,-F,-Br,-Cl,-N02,-NRIoRl l,-C (O) Rg,-C (O) ORg,-ORg,-CN, -OC(O)R8,-NR10C(O)NR10R11,-C(O)NR10R11,-OC(O)NR10R11, -NR10C(O)R13,-C(NR10)NR10R11,-NR10C(O)R11,-NR10C(O)OR9, -NR10C(NCN)SR9,-NR10C(NCN)NR10R11,-C(NCN)NR10R11,-C(NCN)SR9, -NRlOS (0) 2R9,-S ) m'R9,-NRIpC (O) C (O) NR10R11, -NR10C(O) C (O) Rio, thiazolyl, imidazolyl, oxazolyl, pyrazolyl, triazolyl, or tetrazolyl; 0,1,or2;qis R12 is C3-7 cycloalkyl, (2-, 3-or 4-pyridyl), pyrimidyl, pyrazolyl, (1-or 2- imidazolyl), thiazolyl, triazolyl, pyrrolyl, piperazinyl, piperidinyl, morpholinyl, furanyl, (2-or 3-thienyl), (4-or 5-thiazolyl), quinolinyl, naphthyl, or phenyl;

R8 is independently selected from hydrogen or Rg; Rg is R8 or fluorine; R9 is C1-4 alkyl optionally substituted by one to three fluorines; R1o is OR8 or R11; R 11 is hydrogen, or C 1-4 alkyl optionally substituted by one to three fluorines; or when R1o and R 11 are as NR10R11 they may together with the nitrogen form a 5 to 7 membered ring optionally containing at least one additional heteroatom selected from O, N, or S; R13 is oxazolidinyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, thiazolidinyl, isoxazolyl, oxadiazolyl, or thiadiazolyl, and each of these heterocyclic rings is connected through a carbon atom and each may be unsubstituted or substituted by one or two C1-2 alkyl groups; R 14 is hydrogen or R7; or when R1o and R 14 are as NR10R14 they may together with the nitrogen form a 5 to 7 membered ring optionally containing one or more additional heteroatoms selected from O, N, or S; provided that: f) when R12 is N-pyrazolyl, N-imidazolyl, N-triazolyl, N-pyrrolyl, N- piperazinyl, N-piperidinyl, or N-morpholinyl, then q is not 1; or g) when X2R1 is OCF2H or OCF3, X is OCF2H or OCF3, X3 is H, s is zero, X5 is H, Z is C (O) OR14 and R14 is Ci-7 unsubstituted alkyl, then R3 is other than H; or the pharmaceutically acceptable salts thereof.

In a second aspect, this invention relates to the use of a compound of Formula (II) for treating COPD in a mammal, particularly a human, wherein Formula (II) is defined as follows: wherein: <BR> <BR> R1is- (CR4R5) nC (O) O (CR4R5) mR6,- (CR4R5) nC ) NR4(CR4R5) mR6,<BR> <BR> - (CR4R5) nO (CR4R5) mR6, or- (CR4R5) rR6 wherein the alkyl moieties unsubstituted or substituted with one or more halogens; m is 0 to 2;

n is 0 to 4; 0to6;ris R4 and R5 are independently selected hydrogen or C 1-2 alkyl; R6 is hydrogen, methyl, hydroxyl, aryl, halo substituted aryl, aryloxyC 1-3 alkyl, halo substituted aryloxyC 1-3 alkyl, indanyl, indenyl, C7-11 polycycloalkyl, tetrahydrofuranyl, furanyl, tetrahydropyranyl, pyranyl, tetrahydrothienyl, thienyl, tetrahydrothiopyranyl, thiopyranyl, C3_6 cycloalkyl, or a C4-6 cycloalkyl containing one or two unsaturated bonds, wherein the cycloalkyl or heterocyclic moiety is unsubstituted or substituted by 1 to 3 methyl groups, one ethyl group, or an hydroxyl group; provided that: a) when R6 is hydroxyl, then m is 2; or b) when R6 is hydroxyl, then r is 2 to 6; or c) when R6 is 2-tetrahydropyranyl, 2-tetrahydrothiopyranyl, 2-tetrahydrofuranyl, or 2-tetrahydrothienyl, then m is 1 or 2; or d) when R6 is 2-tetrahydropyranyl, 2-tetrahydrothiopyranyl, 2-tetrahydrofuranyl, or 2-tetrahydrothienyl, then r is 1 to 6; e) when n is 1 and m is 0, then R6 is other than H in - (CR4R5) nO (CR4R5) mR6 ; X is YR2, fluorine, NR4R5, or formyl amine; Y is O or S (O) m; m'is 0, 1, or 2; X2 is O or NR8; X3 is hydrogen or X; X4 is H, R9, OR8, CN, C (O) R8, C (O) OR8, C (O) NR8R8, or NR8R8; R2 is independently selected from-CH3 or-CH2CH3 optionally substituted by 1 or more halogens; s is 0 to 4; W is alkyl of 2 to 6 carbons, alkenyl of 2 to 6 carbon atoms or alkynyl of 2 to 6 carbon atoms; R3 is COOR14, C (O) NR4R14 or R7; Z is OR14, S(O)m'R7,S(O)2NR10R14,NR10R14,SR14, NR14C (O) R9, NRIoC (Y) R14, NRIoC (O) OR7, NRIoC (Y) NRIoRl4, NR10S(O)2R7,NR10S(O)2NR10R14,NR10C(NCN)NR10R14, NRlpC (CR4N02) NRlORl4, NRlOC (NCN) SR9, NR10C(CR4NO2)SR9, NR10C(O)C(O)OR14;NR10C(NR10)NR10R14,NR10C(O)C(O)NR10R14,or Y'is OorS;

R7 is- (CR4R5) qR 12 or C 1-6 alkyl wherein the R 12 or C 1-6 alkyl group is unsubstituted or substituted one or more times by methyl or ethyl unsubstituted or substituted by 1-3 fluorines, -F, -Br, -Cl, -NO2, -NR10R11, -C(O)R8, -CO2R8, -CN,-C(O)NR10R11,-O(CH2)qC(O)NR10R11,--O(CH2)2-4OR8,-O(CH2)q R8, O (CH2) qC (O) R9, -NR10C(O)NR10R11, -NR10C(O)R11, -NR10C(O)OR9, -C(NCN)NR10R11,-C(NCN)SR9,-NR10C(O)R13,-C(NR10)NR10R11, -NR I OC (NCN) SR9,-NRIpC (NCN) NR10R11, -NR10S(O)2R9, -S(O)m'R9, -NRloC (O) C (O) NR10R11, -NR10C(O) C (O) Rlo, or R13; q is 0,1, or 2; R12 is R13, C3-C7 cycloalkyl, or an unsubstituted or substituted aryl or heteroaryl group selected from the group consisting of (2-, 3-or 4-pyridyl), pyrimidinyl, pyrazolyl, (1-or 2-imidazolyl), pyrrolyl, piperazinyl, piperidinyl, morpholinyl, furanyl, (2-or 3-thienyl), quinolinyl, naphthyl, and phenyl; R8 is independently selected from hydrogen or R9 ; Rg is C1-4 alkyl optionally substituted by one to three fluorines; OR8orR11;R10is R 1 is hydrogen, or C 1-4 alkyl unsubstituted or substituted by one to three fluorines; or when R1o and R 11 are as NR10R11 they may together with the nitrogen form a 5 to 7 membered ring comprised of carbon or carbon and one or more additional heteroatoms selected from O, N, or S; R 13 is a substituted or unsubstituted heteroaryl group selected from the group consisting of oxazolidinyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, thiazolidinyl, isoxazolyl, oxadiazolyl, and thiadiazolyl, and where Rl3 is substituted on R12 or R13 the rings are connected through a carbon atom and each second Rl3 ring may be unsubstituted or substituted by one or two C1-2 alkyl groups unsubstituted or substituted on the methyl with 1 to 3 fluoro atoms; R14 is hydrogen or R7; or when R8 and R14 are as NRgR14 they may together with the nitrogen form a 5 to 7 membered ring comprised of carbon or carbon and one or more additional heteroatoms selected from O, N, or S; R15 is C (O) R14, C (O) NR8RI4, S (O) qNR8RI4 or S (O) qR7 where q is 0,1 or 2; provided that: (f) R7 is not C1 4 alkyl unsubstituted or substituted by one to three fluorines; or the pharmaceutically acceptable salts thereof.

In a further aspect, this invention relates to a pharmaceutically acceptable composition for treating COPD comprising a pharmaceutically acceptable excipient

and between about 1 and 60mg of a compound of Formula (I) or (II) at least once daily.

Detailed Description of the Invention This invention relates to the use of compounds of Formulas (I) or (II) and to pharmaceutical compositions comprising a compound of Formulas (I) or (II) and a pharmaceutically acceptable carrier or diluent, for treating COPD in a mammal, particularly a human, suffering from COPD. The drug may have use in the prophylaxis of the phenomena associated with COPD before clinical manifestation of the disease in a mammal, particularly a human.

COPD is characterized by a chronic inflammatory process in the lung marked by in increase in the activation and/or number of alveolar macrophages, CD8+ T-cells and neutrophils. Most notably with respect to the therapy of COPD is the ability to alter the trafficking and activation of neutrophils. The neutrophil is believed to play a central role in the pathophysiology of COPD. Neutrophil activation results in the release of a number of inflammatory mediators and proteinases, most importantly neutrophil elastase which contributes to the progressive fibrosis, airway stenosis and destruction of the lung parenchyma, leading to an accelerated decline in airway function. Neutrophil elastase is also a powerful mucus secretagogue and thus may contribute to the characteristic mucus hypersecretion that characterizes COPD. The compounds of this invention have marked effects on neutrophil activity, inhibiting neutrophil chemotaxis and degranulation in vitro. In animal models, the instant compounds reduce neutrophil extravasation from the circulation, pulmonary sequestration and the edematous responses to a number inflammatory insults in vivo.

Additional activities that may contribute to the therapeutic activity of PDE4 inhibitors in COPD include bronchodilation and modulation of pulmonary neuronal activity. Although the degree of reversibility of reduced airway flow is low in COPD, a small increase may have an acute positive effect, as well as a gradual reduction in the slope of the decline which may result in a profound effect on quality of life for COPD patients. The ability of inhaled muscarinc antagonists to produce clinically meaningful improvements in pulmonary function in COPD, at least acutely, suggest that a large component of the reversible airways obstruction in this disease is associated with a dysregulation of pulmonary nerves. Although not studied in detail as yet, PDE4 inhibitors may also modulate the activity of airway epithelial cells, a rich source of proinflammatory mediators that are released upon environmental insult (e. g., smoke), and inhibit vascular smooth muscle hyperplasia, a structural change in end stage COPD that is associated with right heart failure.

The preferred compounds for use in this invention are defined as follows: When R1 for the compounds of the Formula (I) is an alkyl substituted by 1 or more halogens, the halogens are preferably fluorine and chlorine, more preferably a C 1-4 alkyl substituted by 1 or more fluorines. The preferred halo-substituted alkyl chain length is one or two carbons, and most preferred are the moieties-CF3,- CH2F,-CHF2,-CF2CHF2,-CH2CF3, and-CH2CHF2. Preferred Ri substitutents for the compounds of the Formula (I) are CH2-cyclopropyl, CH2-C5-6 cycloalkyl, C4-6 cycloalkyl, C7 11 polycycloalkyl, (3-or 4-cyclopentenyl), phenyl, tetrahydrofuran-3-yl, benzyl or C 1-2 alkyl optionally substituted by 1 or more fluorines,- (CH2) 1-3C (O) O (CH2) 0-2CH3,- (CH2) 1-30 (CH2) 0-2CH3, and - (CH2) 2-40H.

When the Ri term contains the moiety (CR4R5), the R4 and R5 terms are independently hydrogen or alkyl. This allows for branching of the individual methylene units as (CR4Rs) n or (CR4Rs) m; each repeating methylene unit is independent of the other, e. g., (CR4R5) n wherein n is 2 can be-CH2CH (-CH3)-, for instance. The individual hydrogen atoms of the repeating methylene unit or the branching hydrocarbon can optionally be substituted by fluorine independent of each other to yield, for instance, the preferred R1 substitutions, as noted above.

When RI is a C7 11 polycycloalkyl, examples are bicyclo [2.2.1]-heptyl, bicyclo [2.2.2] octyl, bicyclo [3.2.1] octyl, tricyclo [5.2.1. 02,6] decyl, etc. additional <BR> <BR> <BR> <BR> examples of which are described in Saccamano et al., WO 87/06576, published 5 November 1987, whose disclosure is incorporated herein by reference in its entirety.

Z is preferably C (O) Rg, C (O) OR8, C (O) NRgRg, C (NRg) NR8R8, CN, C (NORg) R8, C (O) NRgNR8C (O) R8, C (NRg) NR8R8, C (NCN) NR8R8, C (NCN) SR9, (1-, 4-or 5- {Rg}-2-imidazolyl), (1-, 4-or 5-{R8}-3-pyrazolyl), (1-, 2- or 5- {Rg}-4-triazolyl [1, 2,3]), (1-, 2-, 4-or 5- {Rg}-3-triazolyl [1, 2,4]), (1-or 2- {R8}-5-tetrazolyl), (4-or 5- {Rg}-2-oxazolyl), (3-or 4- {Rg}-5-isoxazolyl), (3- {R8}-5-oxadiazolyl[1, 2,4]), (5-{R8}-3-oxadiazolylf 1,2,4]), (5- {R8}-2-oxadiazolyl[1, 3,4]), (5-{R8}-2-thiadiazolyl [1,3,4]), (4-or or5-{R8}-2-oxazolidinyl),(4-or5-{R8}-2-thiazolyl),(4- 5-{Rg}-2-thiazolidinyl), (1-,{Rg}-2-thiazolidinyl), (1-, 4-or 5-{R8}-2-imidazolidinyl) ; most preferred are those compounds wherein the R8 group of Z is R4.

X5 is preferably hydrogen, C1-2 alkyl optionally substituted by one to three fluorines, ORg, CN, C (O) Rg, C (O) OR8, C (O) NR8R8, or NRgRg.

Preferred X groups for Formula (I) are those wherein X is YR2 and Y is oxygen. The preferred X2 group for Formula (I) is that wherein X2 is oxygen. The preferred X3 group for Formula (I) is that wherein X3 is hydrogen. Preferred R2

groups, where applicable, are C 1-2 alkyl optionally substituted by 1 or more halogens. The halogen atoms are preferably fluorine and chlorine, more preferably fluorine. More preferred R2 groups are those wherein R2 is methyl, or the fluoro- substituted alkyls, specifically a C 1-2 alkyl, such as a-CF3,-CHF2, or-CH2CHF2 moiety. Most preferred are the-CHF2 and-CH3 moieties.

Preferred R3 moieties are C (O) NH2, C=CRg, CN, C (ZH, CH20H, CH2F, CF2H, and CF3. More preferred are-C=CH and CN. Z'is preferably O or NORg.

Preferred R7 moieties include optionally substituted- 1 2 (cyclopropyl), - (CH2) 0-2 (cyclobutyl),- (CH2) 0-2 (cyclopentyl),- (CH2) 0-2 (cyclohexyl), - (CH2) 0-2 (2-, 3-or 4-pyridyl),- (CH2) 1-2 (2-imidazolyl),- (CH2) 2 (4-morpholinyl), - (CH2) 2 (4-piperazinyl),- (CH2) 1-2 (2-thienyl),- (CH2) 1-2 (4-thiazolyl), and - (CH2) 0-2phenyl; Preferred rings when R1o and R 11 in the moiety -NR10R11 together with the nitrogen to which they are attached form a 5 to 7 membered ring optionally containing at least one additional heteroatom selected from O, N, or S include, but are not limited to 1-imidazolyl, 2- (Rg)-1-imidazolyl, 1-pyrazolyl, 2-triazolyl,5-(R8)-1-triazolyl,5-(R8)-2-triazolyl,3-(R8)-1-p yrazolyl,1-triazolyl, 5-(R8)-1-tetrazolyl, 5-(R8)-2-tetrazolyl, 1-tetrazolyl, 2-tetrazloyl, morpholinyl, piperazinyl, pyrrolylring.or Preferred rings when R1o and Ri4 in the moiety -NR10R14 together with the nitrogen to which they are attached may form a 5 to 7 membered ring optionally containing at least one additional heteroatom selected from O, N, or S include, but are not limited to 1-imidazolyl, 1-pyrazolyl, 1-triazolyl, 2-triazolyl, 1-tetrazolyl, 2-tetrazolyl, morpholinyl, piperazinyl, and pyrrolyl. The respective rings may be additionally substituted, where applicable, on an available nitrogen or carbon by the moiety R7 as described herein for Formula (I). Illustrations of such carbon substitutions includes, but are not limited to, 2-(R7)-1-imidazolyl, <BR> <BR> 4-(R7)-1-imidazolyl, 5-(R7)-1-imidazolyl, 3-(R7)-1-pyrazolyl, 4-(R7)-1-pyrazolyl, 5-(R7)-2-triazolyl,4-(R7)-1-triazolyl,5-(R7)-1-pyrazolyl,4-( R7)-2-triazolyl, 5-(R7)-1-triazolyl, 5-(R7)-1-tetrazolyl, and 5- (R7)-2-tetrazolyl. Applicable nitrogen substitution by R7 includes, but is not limited to, 1-(R7)-2-tetrazolyl, 2- (R7)-l-tetrazolyl, 4- (R7)-l-piperazinyl. Where applicable, the ring may be substituted one or more times by R7.

Preferred groups for NR10R14 which contain a heterocyclic ring are 5- (Rl4)-l-tetrazolyl 2-(Rl4)-l-imidazolyl 5-(R14)-2-tetrazolyl, or 4-(RI4)-l- piperazinyl.

Preferred rings for R13 include (2-, 4-or 5-imidazolyl), (3-, 4-or 5-pyrazolyl), (4-or 5-triazolyl [1,2,3]), (3-or 5-triazolyl [1,2,4]), (5-tetrazolyl), (2-, 4- or 5-oxazolyl), (3-, 4-or 5-isoxazolyl), (3-or 5-oxadiazolyl [1,2,4]), (2-oxadiazolyl [1,3,4]), (2-thiadiazolyl [1,3,4]), (2-, 4-, or 5-thiazolyl), (2-, 4-, or 5-oxazolidinyl), (2-, 4-, or 5-thiazolidinyl), or (2-, 4-, or 5-imidazolidinyl).

When the R7 group is optionally substituted by a heterocyclic ring such as imidazolyl, pyrazolyl, triazolyl, tetrazolyl, or thiazolyl, the heterocyclic ring itself may be optionally substituted by R8 either on an available nitrogen or carbon atom, such as 1-(Rg)-2-imidazolyl, 1-(Rg)-4-imidazolyl, 1-(Rg)-5-imidazolyl, 1-(Rg)-3-pyrazolyl, 1-(Rg)-4-pyrazolyl, 1-(Rg)-5-pyrazolyl, 1-(Rg)-4-triazolyl,(Rg)-3-pyrazolyl, 1-(Rg)-4-pyrazolyl, 1-(Rg)-5-pyrazolyl, 1-(Rg)-4-triazolyl, or 1-(Rg)-5-triazolyl.(Rg)-5-triazolyl. Where applicable, the ring may be substituted one or more times by Rg.

Preferred are those compounds of the Formula (I) wherein RI is-CH2- cyclopropyl,-CH2-C5-6 cycloalkyl,-C4-6 cycloalkyl, tetrahydrofuran-3-yl, (3-or 4- cyclopentenyl), benzyl or-C 1-2 alkyl optionally substituted by 1 or more fluorines, and- (CH2) 2-4 OH; R2 is methyl or fluoro-substituted alkyl, R3 is CN or C-CR8; and X is YR2.

Most preferred are those compounds wherein R1 is-CH2-cyclopropyl, cyclopentyl, methyl or CF2H; R3 is CN; X is YR2; Y is oxygen; X2 is oxygen; X3 is hydrogen; and R2 is CF2H or methyl.

A preferred subgenus of the compounds of the Formula (I) is the compounds of the Formula (Ia) wherein: R 1 is CH2-cyclopropyl, CH2-C5-6 cycloalkyl optionally substituted by OH, C4_6 cycloalkyl, C7-11 polycycloalkyl, (3-or 4-cyclopentenyl), phenyl, tetrahydrofuran-3-yl, benzyl or C 1-2 alkyl optionally substituted by 1 or more fluorines,- (CH2) 1-3C (O) O (CH2) 0-2CH3,- (CH2) 1-30 (CH2) 0-2CH3, and - (CH2) 2-40H; X is YR2, halogen, nitro, NR4R5, or formyl amine; X4is

(a) (b) X5 is H, R9, ORg, CN, C (O) R8, C (O) OR8, C (O) NRgRg, or NRgRg; Y is O or S (O) m'; m'is 0, 1, or 2; R2 is-CH3 or-CH2CH3 optionally substituted by 1 or more halogens; R3 is hydrogen, C1-4 alkyl, CH2NHC (O) C (O) NH2, halo-substituted Cl-4 alkyl, CN, CH20Rg, C (Z) C(O)OR8, C (O) NR8RIO, or C=CRg; OorNOR8;Z'is Z is C (O) R14, C (O) OR14, C (O) NRlORl4 C (NR10)NR10R14, CN, C (NORg) R14, C (O) NRgNRgC (O) Rg, C (O) Nr8NR10R14, C (NOR14) Rg, C (NR8) NR10R14, C (NRl4) NRgRg, C (NCN) NR10R14, C (NCN) SR9, (1-, 4-or 5- {R14}-2-imidazolyl), (1-, 4-or 5- {R14}-3-pyrazolyl), (1-, 2-or 5- {R14}-4-triazolyl [1,2,3]), (1-, 2-, 4- or 5-{R14}-3-triazolyl[1, 2,4]), (1-or 2- or5-{R14}-2-oxazolyl),(3-or4-{R14}-5-isoxazolyl),{R14}-5-tet razolyl),(4- (3- {Rlq4}-5-oxadiazolyl [1,2,4]), (5- {R14}-3-oxadiazolyl [1,2,4]), (5-{R14}-2-oxadiazolyl[1, 3,4]), (5- {R14}-2-thiadiazolyl [1,3,4]), (4-or or5-{R14}-2-oxazolidinyl),(4-or5-{R14}-2-thiazolyl),(4- 5-{R14}-2-thiazolidinyl), (l-,{R14}-2-thiazolidinyl), (l-, 4-or 5-{R14}-2-imidazolidinyl); R7 is- (CR4R5) qR 12 or C1-6 alkyl wherein the R 12 or C1-6 alkyl group is optionally substituted one or more times by C 1-2 alkyl optionally substituted by one to three -Br,-Cl,-NO2,-NR10R11,-C(O)R8,-C(O)OR8,-OR8,-CN,-F, -OC(O)R8,-NR10C(O)NR10R11,-C(O)NR10R11,-OC(O)NR10R11, -NR10C(O)R13,-C(NR10)NR10R11,-NR10C(O)R11,-NR10C(O)OR9, -NR10C(NCN)SR9,-NR10C(NCN)NR10R11,-C(NCN)NR10R11,-C(NCN)SR9, -NR10C(O)C(O)NR10R11,-NR10C(O)C(O)R10,-NR10S(O)2R9,-S(O)m'R9 , thiazolyl, imidazolyl, oxazolyl, pyrazolyl, triazolyl, or tetrazolyl; 0,1,or2;qis R12 is C3-C7 cycloalkyl, (2-, 3-or 4-pyridyl), (1-or 2-imidazolyl), piperazinyl, morpholinyl, (2-or 3-thienyl), (4-or 5-thiazolyl), or phenyl; the dotted line formula (a) represents a single or double bond; R8 is independently selected from hydrogen or Rg; Rg is C1-4 alkyl optionally substituted by one to three fluorines; Rlo is OR8 or R11; R 1 is hydrogen or C1-4 alkyl optionally substituted by one to three fluorines; or when R1o and R 1 are as NR1-R11 they may together with the nitrogen form a 5 to 7 membered ring optionally containing at least one additional heteroatom selected from O, N, or S;

R13 is oxazolidinyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, thiazolidinyl, isoxazolyl, oxadiazolyl, or thiadiazolyl, and each of these heterocyclic rings is connected through a carbon atom and each may be unsubstituted or substituted by one or two C1 2 alkyl groups; R14 is hydrogen or R7; or when R1o and R 14 are as NR 1 OR 14 they may together with the nitrogen form a 5 to 7 membered ring optionally containing one or more additional heteroatoms selected from O, N, or S; provided that: a) when R12 is N-imidazolyl, N-triazolyl, N-pyrrolyl, N-piperazinyl, or N- morpholinyl, then q is not 1; or b) when Ri is CF2H or CF3, X is F, OCF2H, or OCF3, X5 is H, Z is C (O) OR14 and R 14 is Ci-7 unsubstituted alkyl, then R3 is other than H; or the pharmaceutically acceptable salts thereof.

The most perferred compounds of Formula (I) are: methyl 4-cyano-4- (3-cyclopentyloxy-4-methoxyphenyl) cyclohex-1-ene-1- carboxylate; 4-cyano-4- (3-cyclopentyloxy-4-methoxyphenyl) cyclohex-1-ene-1-carboxylic acid; methyl cis- [4-cyano-4- (3-cyclopentyloxy-4-methoxyphenyl) cyclohexane-1- carboxylate]; methyl trans- [4-cyano-4- (3-cyclopentyloxy-4-methoxyphenyl) cyclohexane- 1-carboxylate]; methyl cis- [4- (3,4-bisdifluoromethoxyphenyl)-4-cyanocyclohexane-1- carboxylate]; methyl trans- [4- (3, 4-bisdifluoromethoxyphenyl)-4-cyanocyclohexane-1- carboxylate]; cis-[4-cyano-4- (3-cyclopentyloxy-4-methoxyphenyl) cyclohexane-l- carboxylic acid]; cis- [4-cyano-4- (3-cyclopentyloxy-4-methoxyphenyl) cyclohexane-1- carboxylate], tris (hydroxymethyl) ammonium methane salt; cis- [4- (3, 4-bisdifluoromethoxyphenyl)-4-cyanocyclohexane-1-carboxylic acid]; trans- [4-cyano-4- (3-cyclopentyloxy-4-methoxyphenyl) cyclohexane-1- carboxylic acid]; cis-[4-cyano-4- (3-cyclopropylmethoxy-4-methoxyphenyl) cyclohexane-1- carboxylic acid];

trans-[4-cyano-4- (3-cyclopropylmethoxy-4-methoxyphenyl) cyclohexane-1- carboxylic acid]; methyl cis- [4-cyano-4- (3-cyclopropylmethoxy-4- methoxyphenyl)cyclohexane-1-carboxylate]; methyltrans- [4-cyano-4- (3-cyclopropylmethoxy-4- methoxyphenyl)cyclohexane-1-carboxylate]; methylcis- [4-cyano-4- (3-cyclopropylmethoxy-4- difluoromethoxyphenyl)cyclohexane-1-carboxylate]; methyltrans- [4-cyano-4- (3-cyclopropylmethoxy-4-difluoromethoxyphenyl)- cyclohexane-1-carboxylate]; cis-[4-cyano-4- (3-cyclopropylmethoxy-4- difluoromethoxyphenyl) cyclohexane-1-carboxylic acid]; trans- [4-cyano-4- (3-cyclopropylmethoxy-4- difluoromethoxyphenyl) cyclohexane-1-carboxylic acid]; cis- [4-cyano-4- (3- cyclopentyloxy-4-methoxyphenyl) cyclohexane-1-carboxamide] ; cis- [4-cyano-4- (3,4-bisdifluoromethoxyphenyl) cyclohexane-1-carboxamide]; trans- [4-cyano-4- (3,4-bisdifluoromethoxyphenyl) cyclohexane-1-carboxamide]; cis- [4-cyano-4- (3,4- bisdifluoromethoxyphenyl) cyclohexane-1-carbohydrazide]; cis- [4-cyano-4- (3,4- <BR> <BR> bisdifluoromethoxyphenyl) cyclohexane-1- (2-acetylcarbohydrazide)]; cis- {4- (3,4- bisdifluoromethoxyphenyl)-4-cyano-1- (3-methyl [1,2,4] oxadiazol-5- <BR> <BR> yl) cyclohexane}; cis- {4- (3, 4-bisdifluoromethoxyphenyl)-4-cyano-1- (2-<BR> <BR> <BR> methyl [1,3,4] oxadiazol-5-yl) cyclohexane}; cis- {4- (3, 4-bisdifluoromethoxyphenyl)- 4-cyano-1-(2-moethyl[1, 3,4] thiadiazol-5-yl) cyclohexane}; cis- [4-cyano-4- (3- cyclopropylmethoxy-4-methoxyphenyl)-1-hydroxy-1- <BR> <BR> tris (methylthio) methylcyclohexane]; methyl cis- [4-cyano-4- (3-cyclopropylmethoxy-<BR> <BR> <BR> 4-methoxyphenyl)-1-hydroxy-cyclohexane-1-carboxylate];<BR > <BR> <BR> cis- [4-cyano-4- (3-cyclopropylmethoxy-4-methoxyphenyl)-1- hydroxycyclohexane-1-carboxylicacid]; cis- [4-cyano-4- (3-cyclopropylmethoxy-4-methoxyphenyl)-1- hydroxycyclohexane-1-carboxamide]; methyl cis- [4-cyano-4- (3-cyclopropylmethoxy-4-methoxyphenyl)-1- methoxy-cyclohexane-1-carboxylate]; cis-[4-cyano-4- (3-cyclopropylmethoxy-4-methoxyphenyl)-1- methoxycyclohexane-1-carboxylic acid]; <BR> <BR> cis-[4-cyano-4- (3-cyclopropylmethoxy-4-methoxyphenyl)-1-<BR> <BR> <BR> methoxycyclohexane-1-carboxamide]; trans- [4-cyano-4- (3-cyclopropylmethoxy-4-methoxyphenyl)-1-hydroxy- cyclohexane-1-carboxaldehyde];

methyl trans- [4-cyano-4- (3-cyclopropylmethoxy-4-methoxyphenyl)-1-<BR> <BR> <BR> hydroxycyclohexane-1-carboxylate];<BR> <BR> <BR> trans- [4-cyano-4- (3-cyclopropylmethoxy-4-methoxyphenyl)-1- hydroxycyclohexane-1-carboxylic acid]; methyl trans- [4-cyano-4- (3-cyclopropylmethoxy-4-methoxyphenyl)- I- methoxycyclohexane-1-carboxylate]; trans- [4-cyano-4- (3-cyclopropylmethoxy-4-methoxyphenyl)-1- methoxycyclohexane-1-carboxylic acid]; <BR> <BR> trans- [4-cyano-4- (3-cyclopropylmethoxy-4-methoxyphenyl)-1-<BR> <BR> <BR> methoxycyclohexane-1-carboxamide];<BR> <BR> <BR> cis- [4-cyano-4- (3-cyclopentyloxy-4-methoxyphenyl) cyclohexane-1- carboxamic acid]; N-methyl-cis- [4-cyano-4- (3-cyclopentyloxy-4-methoxyphenyl) cyclohexane- 1-carboxamic acid]; cis- [4-cyano-4- (3-cyclopentyloxy-4-methoxyphenyl) cyclohexane-1-N- (2- cyanoethyl)carboxamide]; cis- [1- (2-cyanoethyl)-5- {4-cyano-4- (3-cyclopentyloxy-4- methoxyphenyl) cyclohexyl} tetrazole]; and cis- [4-cyano-4- (3-cyclopentyloxy-4-methoxyphenyl)-1- (tetrazol-5- yl) cyclohexane].

As regards the compounds of Formula (II), the preferred compounds are as follows: When R 1 is an alkyl substituted by 1 or more halogens, the halogens are preferably fluorine and chlorine, more preferably a C 1-4 alkyl substituted by 1 or more fluorines. The preferred halo-substituted alkyl chain length is one or two carbons, and most preferred are the moieties-CF3,-CH2F,-CHF2,-CF2CHF2,- CH2CF3, and-CH2CHF2. Preferred R1 substitutents for the compounds of Formula (I) are CH2-cyclopropyl, CH2-C5-6 cycloalkyl, C4-6 cycloalkyl unsubstituted or substituted with OHC7-11 polycycloalkyl, (3-or 4-cyclopentenyl), phenyl, tetrahydrofuran-3-yl, benzyl or C1-2 alkyl unsubstituted or substituted by 1 or more fluorines,- (CH2) 1-3C (O) O (CH2) 0-2CH3,- (CH2) 1-30 (CH2) 0-2CH3, and - (CH2) 2-40H.

When Ri term contains the moiety (CR4R5), the R4 and Rs terms are independently hydrogen or alkyl. This allows for branching of the individual methylene units as (CR4R5) n or (CR4R5) m; each repeating methylene unit is independent of the other, e. g., (CR4R5) n wherein n is 2 can be-CH2CH (-CH3)-, for instance. The individual hydrogen atoms of the repeating methylene unit or the

branching hydrocarbon can unsubstituted or be substituted by fluorine independent of each other to yield, for instance, the preferred R1 substitutions, as noted above.

When Ri is a C7 11 polycycloalkyl, examples are bicyclo [2.2.1]-heptyl, bicyclo [2.2.2] octyl, bicyclo [3.2.1] octyl, tricyclo decyl, etc. additional <BR> <BR> <BR> examples of which are described in Saccamano et al., WO 87/06576, published 5 November 1987.

W is preferably alkyl, alkenyl or alkynyl of 3 to 5 carbon atoms, and where it is alkenyl or alkynyl, that one or two double or triple bonds be present. It is most preferred that W is ethynyl or 1,3-butadiynyl.

Z is preferably OR14, OR15, SR14, S (O) m'R7, S (0) 2NRlORl4 NR10R14, NR10C(O)OR7,NR10C(O)NR10R14,NR14C(O)R9,NR10C(O)R14, NRIpS (O) 2NRlORl4, NRlpC (NCN) NRlpR14, NRioS (0) 2R7, NRIpC (CR4N02) NRlpRl4, NR10C (NCN) SR9, NR10C(CR4NO2)SR9, orNR10C(O)C(O)OR14.NR10C(NR10)NR10R14,NR10C(O)C(O)NR10R14, Preferred X groups for Formula (I) are those wherein X is YR2 and Y is oxygen. The preferred X2 group for Formula (Ia) is that wherein X2 is oxygen. The preferred X3 group for Formula (I) is that wherein X3 is hydrogen. Preferred R2 groups, where applicable, is a C1-2 alkyl unsubstituted or substituted by 1 or more halogens. The halogen atoms are preferably fluorine and chlorine, more preferably fluorine. More preferred R2 groups are those wherein R2 is methyl, or the fluoro- substituted alkyls, specifically a C 1-2 alkyl, such as a-CF3,-CHF2, or-CH2CHF2 moiety. Most preferred are the-CHF2 and-CH3 moieties.

Preferred R7 moieties include unsubstituted or substituted- (CH2) 0-2 (2-, 3- or 4-pyridyl), (CH2) 1-2 (2-imidazolyl), (CH2) 2 (4-morpholinyl), (CH2) 2 (4- piperazinyl), (CH2) 1-2 (2-thienyl), (CH2) 1-2 (4-thiazolyl), unsubstituted or substituted pyrimidinyl, and substituted or unsubstituted (CH2) 0-2phenyl.

Preferred rings when R1o and R 11 in the moiety -NR10R11 together with the nitrogen to which they are attached form a 5 to 7 membered ring comprised of carbon or carbon and at least one heteroatom selected from O, N, or S include, but are not limited to 1-imidazolyl, 2-(Rg)-1-imidazolyl, 1-pyrazolyl, 3-(R8)-1-pyrazolyl, 1-triazolyl, 2-triazolyl, 5-(Rg)-1-triazolyl, 5-(Rg)-2-triazolyl, 5-(Rg)-1-tetrazolyl, 5-(Rg)-2-tetrazolyl,(Rg)-1-tetrazolyl, 5-(Rg)-2-tetrazolyl, 1-tetrazolyl, 2-tetrazloyl, morpholinyl, piperazinyl, pyrrolylring.or Preferred rings when R1o and R 14 in the moiety -NR10R14 together with the nitrogen to which they are attached may form a 5 to 7 membered ring comprised of carbon or carbon and at least one heteroatom selected from O, N, or S include, but are not limited to 1-imidazolyl, 1-pyrazolyl, 1-triazolyl, 2-triazolyl, 1-tetrazolyl,

2-tetrazolyl, morpholinyl, piperazinyl, and pyrrolyl. The respective rings may be additionally substituted, where applicable, on an available nitrogen or carbon by the moiety R7 as described herein for Formula (I). Illustrations of such carbon substitutions includes, but is not limited to, 2- (R7)-l-imidazolyl, <BR> <BR> <BR> 4-(R7)-l-imidazolyl, 5-(R7)-1-imidazolyl, 3-(R7)-1-pyrazolyl, 4-(R7)-1-pyrazolyl,<BR> <BR> <BR> <BR> <BR> <BR> 5- (R7)-l-pyrazolyl, 4- (R7)-2-triazolyl, 5- (R7)-2-triazolyl, 4- (R7)-l-triazolyl, 5- (R7)-1-triazolyl, 5- (R7)-1-tetrazolyl, and 5- (R7)-2-tetrazolyl. Applicable nitrogen substitution by R7 includes, but is not limited to, 1- (R7)-2-tetrazolyl, 2- (R7)-1-tetrazolyl, 4- (R7)-1-piperazinyl. Where applicable, the ring may be substituted one or more times by R7.

Preferred groups for NR1oRl4 which contain a heterocyclic ring are 5- (R14)-1-tetrazolyl, 2-(Rl4)-1-imidazolyl, 5-(R14)-2-tetrazolyl, 4-(R14)-1- piperazinyl, or 4-(R15)-l-piperazinyl.

Preferred rings for R13 include (2-, 4-or 5-imidazolyl), (3-, 4-or 5-pyrazolyl), (4-or 5-triazolyl [1,2,3]), (3-or 5-triazolyl [1,2,4]), (5-tetrazolyl), (2-, 4- or 5-oxazolyl), (3-, 4-or 5-isoxazolyl), (3-or 5-oxadiazolyl [1,2,4]), (2-oxadiazolyl [1,3,4]), (2-thiadiazolyl [1,3,4]), (2-, 4-, or 5-thiazolyl), (2-, 4-, or 5-oxazolidinyl), (2-, 4-, or 5-thiazolidinyl), or (2-, 4-, or 5-imidazolidinyl).

When the R7 group is unsubstituted or substituted by a heterocyclic ring such as imidazolyl, pyrazolyl, triazolyl, tetrazolyl, or thiazolyl, the heterocyclic ring itself may be unsubstituted or substituted by R8 on an available nitrogen or carbon atom, such as 1-(Rg)-2-imidazolyl, 1-(Rg)-4-imidazolyl, 1-(Rg)-5-imidazolyl, 1- (Rg)-3-pyrazolyl, 1- (Rg)-4-pyrazolyl, 1- (Rg)-5-pyrazolyl, 1- (Rg)-4-triazolyl, or 1-(Rg)-5-triazolyl.(Rg)-5-triazolyl. Where applicable, the ring may be substituted one or more times by Rg.

Preferred are those compounds of Formula (II) wherein R 1 is-CH2- cyclopropyl,-CH2-C5-6 cycloalkyl,-C4-6 cycloalkyl unsubstituted or substituted by OH, tetrahydrofuran-3-yl, (3-or 4-cyclopentenyl), benzyl or-C l-2 alkyl unsubstituted or substituted by 1 or more fluorines, and- (CH2) 2-4 OH; R2 is methyl or fluoro-substituted alkyl, W is ethynyl or 1,3-butadiynyl; R3 is R7 where R7 is an unsubstituted or substituted aryl or heteroaryl ring, X is YR2, and Z is OR14, OR15, NRloRl4, or NR14C (O) Rg.

Most preferred are those compounds of Formula (II) wherein Ri is -CH2-cyclopropyl, cyclopentyl, 3-hydroxycyclopentyl, methyl or CF2H; X is YR2; Y is oxygen; X2 is oxygen; X3 is hydrogen; and R2 is CF2H or methyl, W is ethynyl or 1,3-butadiynyl, and R3 is a substituted or unsubstituted pyrimidinyl ring.

The most preferred compounds of Formula (II) are:

cis- [4- (2-aminopyrimidin-5-ylethynyl)-4- (3-cyclopentyloxy-4- methoxyphenyl) cyclohexan-1-ol], <BR> <BR> cis- [4- (2-aminopyrimidin-4-ylethynyl)-4- (3-cyclopentyloxy-4-<BR> <BR> <BR> methoxyphenyl)-cyclohexan-1-ol],<BR> <BR> <BR> trans- [4- (2-acetamidopyrimidin-5-ylethynyl)-4- (3-cyclopentyloy-4- methoxyphenyl) cyclohexan-1-ol], <BR> <BR> trans- [4- (2-aminopyrimidin-5-yl-ethynyl)-4- (3-cyclopentyloxy-4-<BR> <BR> <BR> methoxyphenyl)-cyclohexan-1-ol,<BR> <BR> <BR> cis- [4- (2-methylaminopyrimidin-5-ylethynyl)-4- (3-cyclopentyloxy-4- methoxyphenyl) cyclohexan-1-ol], cis- [4- (3-cyclopentyloxy-4-methoxyphenyl)-4- (pyrid-4- ylethynyl)cyclohexan-1-ol], cis- [4- (3-cyclopentyloxy-4-methoxyphenyl)-4- (pyrid-2- ylethynyl)cyclohexan-1-ol], <BR> <BR> cis- [4- (4-cyanothien-2-ylethynyl)-4- (3-cyclopentyloxy-4-methoxyphenyl)-<BR> <BR> <BR> cyclohexan-1-ol],<BR> <BR> <BR> cis-[4- (thiazol-2-ylethynyl)-4- (3-cyclopentyloxy-4- methoxyphenyl) cyclohexan-1-ol], cis-[4- (3-cyclopentyloxy-4-methoxyphenyl)-4- [4- (5-methyl- [1,2,4] oxadiazol-2-yl) thien-2-ylethynyl] cyclohexan-1-ol], cis- [4- (3-cyclopentyloxy-4-methoxyphenyl)-4- (2- [3- (3- methyl [1,2,4] oxadiazol-5-yl) phenyl] ethynyl) cyclohexan-1-ol], cis- [4- (3-cyclopentyloxy-4-methoxyphenyl)-4- (2- [3- (5- methyl [1,3,4] oxadiazol-2-yl) phenyl] ethynyl) cyclohexan-1-ol], cis-[4- (3-cyclopentyloxy-4-methoxyphenyl)-4- (2- [3- (5- methyl [1,2,4] oxadiazol-3-yl) phenyl] ethynyl) cyclohexan-1-ol], cis-4- (3-cyclopentyloxy-4-methoxyphenyl)-4- [3- (5-trifluoromethyl- [1,2,4] oxadiazol-3-yl) phenylethynyl) cyclohexan-1-ol, cM-4- (3-cyclopentyloxy-4-methoxyphenyl)-4- [3- (5-methyl- [l, 3,4] thiadiazol- 2-yl) phenylethynyl] cyclohexan-1-ol, trans- [4- (3-cyclopentyloxy-4-methoxyphenyl)-4- (pyrid-2- ylethynyl) cyclohexyl-1-amine], trans- [4- (3-cyclopentyloxy-4-methoxyphenyl)-4- (pyrid-2- ylethynyl) cyclohexyl-1-formamide], trans- [4- (3-cyclopentyloxy-4-methoxyphenyl)-4- [5- (5-methyl- [1,2,4] oxadiazol-2-yl) thien-2-ylethynyl] cyclohexyl-1-amine], cyclohexylsulfamate salt

cis- [4- (3-cyclopentyloxy-4-methoxyphenyl)-4- (pyrid-2- ylethynyl)cyclohexyl-1-amine], cis- [4- (3-cyclopentyloxy-4-methoxyphenyl)-4- (pyrid-2- ylethynyl)cyclohexyl-1-formamide], cis- [4- (3-cyclopentyloxy-4-methoxyphenyl)-4- [5- (5-methyl- [1,2,4] oxadiazol-2-yl) thien-2-ylethynyl] cyclohexyl-l-amine], cyclohexylsulfamate salt, trans- [4- (2-aminopyrimidin-5-ylethynyl)-4- (3-cyclopentyloxy-4- methoxyphenyl) cyclohexyl-1-amine], cyclohexylsulfamate salt, or cis- [4- (2-aminopyrimidin-5-ylethynyl)-4- (3-cyclopentyloxy-4- methoxyphenyl) cyclohexyl-1-amine], cyclohexylsulfamate salt.

Some compounds of Formula (I) and Formula (II) may exist in both racemic and optically active forms; some may also exist in distinct diastereomeric forms possessing distinct physical and biological properties. All of these compounds are considered to be within the scope of the present invention. Therefore another aspect of the present invention is the administration of either a racemate, a single enantiomeric form, a single diastereomeric form, or mixtures thereof.

The terms cis and trans denote stereochemistry at the C-1 position of the cyclohexane ring relative to the R3 group at the C-4 position.

The terms"C 1 3 alkyl","C 1 4 alkyl","C 1 _6 alkyl"or"alkyl"include both straight or branched chain radicals of 1 to 10, unless the chain length is limited thereto, including, but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, sec- butyl, isobutyl, tert-butyl, and the like."Alkenyl"includes both straight or branched chain radicals of 1 to 6 carbon lengths, unless the chain length is limited thereto, including but not limited to vinyl, 1-propenyl, 2-propenyl, 2-propynyl, or 3-methyl- 2-propenyl."Cycloalkyl"or"cycloalkyl alkyl"includes groups of 3-7 carbon atoms, such as cyclopropyl, cyclopropylmethyl, cyclopentyl, or cyclohexyl."Aryl"or "aralkyl", unless specified otherwise, means an aromatic ring or ring system of 6-10 carbon atoms, such as phenyl, benzyl, phenethyl, or naphthyl. Preferably the aryl is monocyclic, i. e, phenyl. The alkyl chain includes both straight or branched chain radicals of 1 to 4 carbon atoms."Heteroaryl"as used herein, is meant an aromatic ring system containing one or more heteroatoms, such as imidazolyl, triazolyl, oxazolyl, pyridyl, pyrimidyl, pyrazolyl, pyrrolyl, furanyl, or thienyl."Halo"as used herein is meant all halogens, i. e., chloro, fluoro, bromo, or iodo.

METHODS OF PREPARATION: The preparation of compounds of Formula (I) is fully set forth in U. S. patent 5,552,438 issued 3 September 1996. This patent is incorporated herein in its

entirety by reference as if fully set out herein. The compounds of Formula (II) are known compound and can be prepared by the methods set out in published PCT application PCT/US95/16711 published as W096/19988 on 4 July 1996 or PCT/US96/08080 published as W096/38150 on 05 December 1996. The contents of these published PCT applications are incorporated herein by reference as if fully set forth herein.

METHODS OF TREATMENT In order to use a compound of Formula (I) and (II) or a pharmaceutically acceptable salt thereof for the treatment of COPD, it will be formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

The compounds of Formula (I) and (II) or a pharmaceutically acceptable salt, polymorph, hydrate, etc., thereof can be used in the manufacture of a medicament for the prophylatic or therapeutic treatment of COPD.

The pharmaceutical composition of the present invention will comprise an effective, non-toxic amount of a compound of Formula (I) or (II) and a pharmaceutically acceptable carrier or diluent. The compounds of Formula (I) and (In are administered in conventional dosage forms prepared by combining a compound of Formula (I) and (II) in an amount sufficient to reduce COPD symptoms and/or its progression, with standard pharmaceutical carriers according to conventional procedures. These procedures may involve mixing, granulating, and compressing or dissolving the ingredients as appropriate to the desired preparation.

Thus, if a solid carrier is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form, or in the form of a troche or lozenge.

The amount of solid carrier will vary widely but preferably will be from about 25 mg to about 1 gram. When a liquid carrier is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension. Where the composition is in the form of a capsule, any routine encapsulation is suitable, for example using the aforementioned carriers in a hard gelatin capsule shell. Where the composition is in the form of a soft gelatin shell capsule any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be considered, for example aqueous gums, celluloses, silicates, or oils and are incorporated in a soft gelatin capsule shell. A syrup formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, glycerine, or water with a flavoring or coloring agent.

The daily dosage regimen for oral administration is suitably about. 001 mg/kg to 100mg/kg, preferably 0.01 mg/Kg to 40 mg/Kg, of a compound of Formula (I) and (II) or a pharmaceutically acceptable salt thereof calculated as the free base. The

active ingredient may be administered from 1 to 6 times a day, sufficient to exhibit activity.

While it is possible for an active ingredient to be administered neat, it is preferable to present it as a pharmaceutical formulation. The active ingredient may comprise, for topical administration, from 0.001% to 10% w/w, e. g., from 1% to 2% by weight of formulation, although it may comprise as much as 10% w/w but preferably not in excess of 5% w/w and more preferably from 0.1% to 1% w/w of Formulation.

It will be recognized by one of skill in the art that the form and character of the pharmaceutically acceptable carrier or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration, and other well-known variables.

Formulations of the present invention comprise an active ingredient together with one or more acceptable carrier (s) thereof and optionally any other therapeutic ingredient (s). The carrier (s) must be'acceptable'in the sense of being compatible with the other ingredients of Formulation and not deleterious to the recipient thereof.

The preferred pharmaceutical formulation is an oral formulation and one which contains between about 1 mg and 60mg of a compound of formula (I) or formula (II) at least once a day to a patient suffering from COPD or who is at risk for developing COPD. Perferably the formulation will be a tablet or similar solid dosage form such as an immediate release tablet. The more preferred formulation is a tablet which contains Formula (I) or Formula (II) in an amount of Smg, 10mg, 15mg or 20mg. Most perferably the formulation will be an immediate release tablet which contain about 15mg of a compound; perferably the compound will be cis- [4- cyano-4- (3-cyclopentyloxy-4-methoxyphenyl) cyclohexane-l-carboxylic acid]; or a pharmaceutically acceptable salt, polymorph, pro-drug, or hydrate thereof.

This invention relates to a method for treating COPD in a human suffering from COPD, or for preventing or reducing the intensity of the onset of COPD in a human, by administering at least once daily a pharmaceutical composition containing a compound of Formula (I) or Formula (II) in an amount between lmg and 20mg admixed with a pharmaceutically acceptable excipient. More preferably the methods comprise administering a composition which contains Smg, lOmg, 15mg or 20 mg at least twice daily. Most preferably the compound will contain about 15mg of cis- [4- cyano-4- (3-cyclopentyloxy-4-methoxyphenyl) cyclohexane-l-carboxylic acid]; or a pharmaceutically acceptable salt, polymorph, or hydrate thereof and will be administered twice daily. And perferably the composition will be administered as a tablet and will be administered orally.

Example 1 Tablet Formulation A tablet was prepared as described further herein using as the active ingredient cis- [4-cyano-4- (3-cyclopentyloxy-4-methoxyphenyl) cyclohexane-1- carboxylic acid] and the excipients listed in Table 1.

Table 1 Ingredient IngredientQuantity (mg/tablet) cis- [4-cyano-4- (3-cyclopentyloxy-4-methoxyphenyl) cyclohexane- 15.0 1-carboxylicacid]; Lactose monohydrate 103.0 Microcrystalline cellulose 70.0 Sodium starch glycolate 10.0 Magnesium stearate 2.0 Opadry Yellow OY-S-22907 5.0 Purified water purified water is removed by drying during the q. s. application of the coating suspension. AFC Tablet Weight 205 Tabletshape octagonal The ingredients are separately weighed and screened. The active ingredient is mixed with lactose monohydrate, microcrystalline cellulose and sodium starch glycolate. Magnesium stearate is added to the mixture. The blend is compressed and the tablet cores are coated with an aqueous film coat.

Blending Initial step: Weigh the acid, lactose, microcrystalline cellulose, sodium starch glycolate and magnesium stearate. Screen each ingredient to de-aggregate using a vibratory/shaker separator or equivalent, fitted with a suitable sieve screen.

Step 2: Charge a bin blender or equivalent with the microcrystalline cellulose, sodium starch glycolate, SB-207499 and lactose. Mix until a homogeneous blend is achieved (approximately 20 minutes).

Step 3: Add the magnesium stearate to the blender. Blend for approximately 3 minutes.

Compression and Coating Step 1: Compress the tablets using a rotary tablet press or equivalent.

Step 2: Prepare a 12 % w/w Opadry coating suspension, using 7. 33 grams of purified water/gram of Opadry.

Step 3: Using a perforated pan coating system or equivalent, spray the coating suspension on the tablet cores until the desired tablet weight gain is obtained.

Step 4: Dry the tablets.

No toxic effects are expected when these compounds are administered in accordance with the present invention.